Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 172

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

CRL4AMBRA1 is a master regulator of D-type cyclins

Open access
Simoneschi, Daniele, Rona, Gergely, Zhou, Nan, Jeong, Yeon-Tae, Jiang, Shaowen, Milletti, Giacomo, Arbini, Arnaldo A., O’Sullivan, Alfie, Wang, Andrew A., Nithikasem, Sorasicha, Keegan, Sarah, Siu, Yik, Cianfanelli, Valentina, Maiani, Emiliano, Nazio, Francesca, Cecconi, Francesco, Boccalatte, Francesco, Fenyö, David, Jones, Drew R., Busino, Luca, Pagano, Michele·2021·Nature

Abstract

D-type cyclins are central regulators of the cell division cycle and are among the most frequently deregulated therapeutic targets in human cancer1, but the mechanisms that regulate their turnover are still being debated2,3. Here, by combining biochemical and genetics studies in somatic cells, we identify CRL4AMBRA1 (also known as CRL4DCAF3) as the ubiquitin ligase that targets all three D-type cyclins for degradation. During development, loss of Ambra1 induces the accumulation of D-type cyclins and retinoblastoma (RB) hyperphosphorylation and hyperproliferation, and results in defects of the nervous system that are reduced by treating pregnant mice with the FDA-approved CDK4 and CDK6 (CDK4/6) inhibitor abemaciclib. Moreover, AMBRA1 acts as a tumour suppressor in mouse models and low AMBRA1 mRNA levels are predictive of poor survival in cancer patients. Cancer hotspot mutations in D-type cyclins abrogate their binding to AMBRA1 and induce their stabilization. Finally, a whole-genome, CRISPR–Cas9 screen identified AMBRA1 as a regulator of the response to CDK4/6 inhibition. Loss of AMBRA1 reduces sensitivity to CDK4/6 inhibitors by promoting the formation of complexes of D-type cyclins with CDK2. Collectively, our results reveal the molecular mechanism that controls the stability of D-type cyclins during cell-cycle progression, in development and in human cancer, and implicate AMBRA1 as a critical regulator of the RB pathway. Biochemical and genetics studies identify CRL4AMBRA1 as the ubiquitin ligase that has a key role in regulating the stability of D-type cyclins during cell-cycle progression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-021-03445-y

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 172

Metadata

Authors
Simoneschi, D., Rona, G., Zhou, N., Jeong, Y.-T., Jiang, S., Milletti, G., Arbini, A. A., O’Sullivan, A., Wang, A. A., Nithikasem, S., Keegan, S., Siu, Y., Cianfanelli, V., Maiani, E., Nazio, F., Cecconi, F., Boccalatte, F., Fenyö, D., Jones, D. R., Busino, L., & Pagano, M.
Venue
Nature
Published
2021-04-14
Volume
592
Issue
7856
Pages
789-793
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W3156007823
Cited by
172
References
9
FWCI
7.11
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CRL4AMBRA1 is a master regulator of D-type cyclins. https://app.cochat.ai/papers/10.1038/s41586-021-03445-y
The paper
Simoneschi, D., Rona, G., Zhou, N., Jeong, Y.-T., Jiang, S., Milletti, G., Arbini, A. A., O’Sullivan, A., Wang, A. A., Nithikasem, S., Keegan, S., Siu, Y., Cianfanelli, V., Maiani, E., Nazio, F., Cecconi, F., Boccalatte, F., Fenyö, D., Jones, D. R., . . . Pagano, M. (2021). CRL4AMBRA1 is a master regulator of D-type cyclins. Nature. https://doi.org/10.1038/s41586-021-03445-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.